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Background and purpose: The role of autophagy in response to ischemic stroke has been confusing with reports that
both enhancement and inhibition of autophagy decrease infarct size and improve post-stroke outcomes. We sought to
clarify this by comparing pharmacologic modulation of autophagy in two clinically relevant murine models of stroke.
Methods: We used rapamycin to induce autophagy, and chloroquine to block completion of autophagy, by treating
mice immediately after stroke and at 24 hours post-stroke in two different models; permanent Middle Cerebral Artery
Ligation (MCAL), which does not allow for reperfusion of distal trunk of middle cerebral artery, and Embolic Clot Middle
Cerebral Artery Occlusion (eMCAO) which allows for a slow reperfusion similar to that seen in most human stroke
patients. Outcome measures at 48 hours post-stroke included infarct size analysis, behavioral assessment using
Bederson neurological scoring, and survival.
Results: Chloroquine treatment reduced the lesion size by approximately 30% and was significant only in the eMCAO
model, where it also improved the neurological score, but did not increase survival. Rapamycin reduced lesion size by
44% and 50% in the MCAL and eMCAO models, respectively. Rapamycin also improved the neurological score to a
greater degree than chloroquine and improved survival.
Conclusions: While both inhibition and enhancement of autophagy by pharmacological intervention decreased lesion
size and improved neurological scores, the enhancement with rapamycin showed a greater degree of improvement in
outcomes as well as in survival. The protective action seen with chloroquine may be in part due to off-target effects on
apoptosis separate from blocking lysosomal activity in autophagy. We conclude pharmacologic induction of autophagy
is more advantageous than its blockade in physiologically-relevant permanent and slow reperfusion stroke models.
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Autophagy, a cell survival process has recently been rec-
ognized as being involved in human strokes [1,2]. The
major form of autophagy, macroautophagy (referred to
as autophagy herein), is a cellular process that normally
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reproduction in any medium, provided the orvesicular seclusion followed by lysosomal degradation. It
helps in reclaiming essential nutrients and molecular
components and can be an alternative source of ATP. It
is up regulated by cellular stressors, including nutrient
deprivation, ischemia and reactive oxygen species (ROS)
to enhance cell survival. In that many of these same
stressors occur in ischemic stroke, it is of interest to
understand the role of autophagy following stroke
[1,3,4]. Autophagy has been implicated in recovery from
cardiac ischemia [5], and also retards the progression ofl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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may underlie a number of CNS disorders. Normal regu-
lation of protective autophagy may be overwhelmed
following large ischemic injuries, which either allow
apoptotic cell death to precede, or even lead to an au-
tophagic mediated form of cell death [7]. As such, it is
controversial whether increasing, or inhibiting, autoph-
agy is protective following stroke. While autophagy has
been studied in animal models of adult and neonatal
brain ischemia, most of the studies are inconclusive, or
have produced contradictory outcomes [1,3,4,7]. This
lack of consensus on the role of autophagy in stroke
injury may in large part be due to methodological
approaches where autophagy has been either “induced”
or “inhibited”, but not compared side by side in the
same study. Confounding the issue, some of the au-
tophagy inhibitors used can also inhibit apoptotic path-
ways, or can even increase autophagy with prolonged
treatment [8].
The type of ischemic models used, in particular
“permanent ischemia” or slow reperfusion vs rapid reper-
fusion models, may also impact the outcome of manipu-
lating autophagy pathways as has been reported in some
myocardial infarction studies [9]. Importantly, the use of
pre-clinical animal stroke models that more closely and
effectively model key physiologic mechanisms involved in
human stroke has been highlighted as critical to success
in therapeutic human clinical trials [10,11]. To date there
has been almost universal failure of neuroprotection
based clinical trials following successful pre-clinical ani-
mal studies.
Following ischemic cerebral stroke two major vascular
pathophysiological processes impact stroke outcomes
and should be considered in pre-clinical models to more
effectively mimic human stroke injury. The first is the
severity of the cerebral blood flow (CBF) reduction and
the second is the dynamics of CBF restoration [11]. The
severity of CBF reduction is critical in human stroke and
several pre-clinical rodent models effectively address this
aspect. However, dynamics of CBF restoration are fre-
quently not modeled closely. Rapid complete reperfusion
where the timing of the reperfusion is prior to irrevers-
ible ischemic core damage and penumbral tissue necro-
sis, is quite different from the type of reperfusion seen in
human stroke either with, or without, tPA treatment or
surgical thromboectomy. Indeed even timely tPA or
thromboectomy treatments, which are available to less
than 5 percent of all patients, have significantly different
reperfusion characteristics than most animal models of
stroke [12]. As such the most commonly used rodent
models, including transient suture occlusion of the mid-
dle cerebral artery (tsMCAO), result in non-physiologic
rapid reperfusion. Early, rapid reperfusion involves sig-
nificant differences in a number of aspects including:vascular dynamics (e.g. degree of reperfusion, reperfusion
pressure, blood viscosity, vessel dilation, no reflow) and
endothelial cell responses, reactive oxygen species produc-
tion, downstream micro-infarction from degraded embolic
clots, and bioactive clot derived molecules [10,11]. Full
restoration of cerebral blood flow within 3–6 hours, de-
pending on the initial size of the ischemic region, can
potentially preserve penumbral tissue outside the ische-
mic core, though tissue recovery within the ischemic
core requires an even shorter time window, and this
penumbral tissue is then vulnerable to secondary cell
death mechanisms [10,11]. However, within these time
frames most human cases remain either non-reperfused,
or are only partially reperfused in a delayed fashion, due
to limited self-recanalization [10,11]. Therefore, to more
closely replicate human CBF dynamics two different
stroke models were used here. First, a middle cerebral ar-
tery ligation (MCAL) model was used that produces a
permanent occlusion with similarities to small non-
reperfused human stroke [11]. Second, we also included
a more physiologically relevant murine embolic clot mid-
dle cerebral artery occlusion (eMCAO) model [13,14].
This model uses embolic clots prepared from murine
blood stabilized with human fibrinogen to permit slow
self-recanalization over the course of 24-plus hours.
In this study, we examined the effect of pharmacologic
modulation of autophagy as a treatment strategy to pro-
tect brain tissue from nutrient and energy deficits with
delayed reperfusion [11,13]. Given the confusion of scien-
tific literature on the role of autophagy, in this initial study
we used two pharmacological agents to drive (rapamycin),
or block (chloroquine), autophagy. We tested the hypoth-
esis that inducing autophagy during ischemia in permanent
and slow partial reperfusion stroke models is advantageous




C57BL/6 J male mice were purchased from Jackson
Laboratories (Bar Harbor, ME). Animals were maintained
at the Animal Research Facility of the Charlie Norwood
Veterans Affairs Medical Center (VAMC) with free access
to chow diet, water ad-libitum and 12 hours light/dark
cycle. We used either 8–12 or 20–22 weeks old mice for
MCAL or eMCAO, respectively. We chose to use young
mice in the MCAL model experiments based on our ex-
tensive preliminary studies establishing dose and timing of
rapamycin and chloroquine treatments [13,14]. However,
we used older mice with the eMCAO model based on our
experience with the development of that model and in-
creased physiologic relevancy of using older mice [13-15].
Experiments were conducted in accordance with the
guidelines set by the Institutional Animal Care and Use
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Georgia Regents University.
Immunoblotting
Tissues were homogenized and lysed in 2× Laemmli
lysis buffer, as previously described [16]. Membranes
were re-probed with mouse monoclonal anti-GAPDH
(G8795, Sigma-Aldrich Co.) and β-actin (A5441, Sigma-
Aldrich Co.) as loading controls. All loading was based
on EZQ™ Protein Quantitation Kit (Life Technologies)
for equal loading. The two loading controls were used
because we were looking at different tissues with very
different cellular and extracellular protein expression.
β-actin has proven to be useful for most tissues as a
house-keeping gene, however it is not well expressed in
muscle tissues. Consequently we also used GAPDH as
a house-keeping control, which is expressed in muscle.
However, its expression can vary across different tis-
sues as well. Therefore, we included both loading con-
trols. Proteins were visualized by ECL (Pierce, Thermo
Fisher Scientific) using autoradiography film (Denville
Scientific). The intensity of the immunoreactive bands
was quantified by densitometry using Image J 1.44p
software (NIH). All quantitations were performed off film
exposed for one minute with equal antibody concentra-
tions used on each tissue.
Middle cerebral artery ligation (MCAL) stroke model
The MCAL surgery was performed as described previ-
ously with minor modifications [11]. A 2 – 3 mm burr
hole was drilled at the junction of the zygomatic arch
and the squamous bone. The main trunk of left MCA
was exposed and electrocauterized distal to the lenti-
culostriate branches. The treatments were injected
intra-peritoneal (IP) immediately after occlusion and
repeated at 24 hours post-stroke. Animals were euthanized
and tissue collected at 48 hours post-stroke as previously
described [13].
Embolic middle cerebral artery occlusion (eMCAO)
stroke model
The murine eMCAO stroke model, using human fi-
brinogen (hu-fibrinogen) to stabilize the clot, was per-
formed as recently reported [13,14]. Our eMCAO model
was modified with human fibrinogen to improve stability
and reproducibility [13,14]. Subsequently, other groups
have also published that the addition of fibrinogen in-
creases reproducibility in different rodent species. Dur-
ing the standardization of the embolic model using
partially humanized clots, we studied the immune re-
sponses to injury either immunizing the mouse with
higher (1 mg/kg) hu-fibrinogen or by released with clot lys-
ate generated by using tPA/plasminogen thrombolysis.
There were no significant differences in stroke outcomesfrom controls (data not shown). Additionally, no xenogenic
immune effects have been reported by other laboratories
[17-19]. The treatments and euthanasia were performed as
described for MCAL.
Pharmacological treatments
Normal control (no surgery, no treatment); vehicle con-
trol (either of the stroke surgeries followed by IP 40%
DMSO for rapamycin in initial studies, or saline for
chloroquine and follow up studies, treatment); rapamy-
cin (Selleck, S1039; 0.625, 1.25, 2.5 mg/kg prepared in
4:10 DMSO:saline); chloroquine (Sigma-Aldrich Co.,
C6628; 30, 60, 90 mg/kg prepared in saline) groups were
used (Additional file 1: Figure S1).
Neurological assessment
Neurological deficits in the animals were assessed at
48 hours post-stroke using a modified 5-point Bederson
scale, as described in detail previously [13,14]. 0, no
deficit; 1, forelimb flexion deficit on contralateral side;
2, decreased resistance to lateral push and torso turn-
ing to the ipsilateral side when held by tail; 3, very sig-
nificant circling to affected side and reduced capability to
bear weight on the affected side; 4, animal rarely moves
spontaneously and prefers to lay down or stay at rest.
Infarct analysis
Infarct analysis was performed on 2,3,5-triphenyltetrazo-
lium chloride (TTC; Sigma-Aldrich Co.) stained sections
as described previously [13,14]. Brains were perfused
with ice cold 0.01 M phosphate-buffered saline (PBS), cut
into 1-mm coronal slices, stained by TTC for 30 minutes
at 37°C, then fixed with 10% formalin in PBS. The images
were digitalized and the infarct volume was analyzed by
Image J software outlining the ipsilateral and contralat-
eral hemispheres, excluding the infarcted tissue and in-
cluding the infarcted region (if the fragile ischemic
tissue fell out of the slice the original contour over that
small area was derived from the corresponding contra-
lateral zone after inversion. The infarct volumes were
quantified as both direct volume (in mm3) and indirect
volume (percent volume of the total ischemic hemisphere).
An investigator blinded to treatment groups analyzed the
infarct size.
Autophagic flux
To assess autophagic flux in vivo, 22 week old mice were
treated with 60 mg/kg chloroquine IP for five to six
hours (n = 4) and compared to aged-matched controls
receiving saline (n = 5). Mice were sacrificed by CO2
asphyxiation followed by thoracotomy. Tissues (Brain,
lungs, heart, quadriceps muscle, spleen, kidney, and liver)
were dissected and immediately snap-frozen in liquid ni-
trogen. The time and potential methods for autophagic
Buckley et al. Experimental & Translational Stroke Medicine 2014, 6:8 Page 4 of 9
http://www.etsmjournal.com/content/6/1/8flux assessment using inhibition of flux by chloroquine was
modified from Klionsky et al. [20]. Tissues were processed
for immunoblotting as described above.
Statistical analyses
All the data are expressed as mean ± SD. Assumptions of
normality were tested and rank transforamations were
used as needed. Data were analyzed using SAS 9.3 soft-
ware (SAS Institute Inc., Cary, NC). Two-sample t-tests
were used to compare LC3 (I and II) quantitation of non-
muscle, muscle and CQ treated brain tissue to non-treated
brain tissue. A one-way analysis of variance (ANOVA) was
used to determine dose effects for rapamycin or chloro-
quine. Infarct volume and neurological deficit were ana-
lyzed using a 2 rapamycin (none vs. 1.25 mg/kg) by 2
chloroquine (none vs. 60 mg/kg) ANOVA. An interaction
was tested and if significant would indicate a differential ef-
fect of rapamycin in the presence of chloroquine. Tukey’s
post-hoc tests were to adjust for multiple comparisons for
significant ANOVA effects. Survival at 48 hours was ana-
lyzed using a Cochran-Mantel-Haenszel test. Null hypoth-
eses were rejected at p ≤ 0.05.
Results
Autophagy in the brain
We demonstrated that the brain has the highest level of
autophagy relative to other metabolically active tissues.
The basal level of LC3 (microtubule-associated protein 1
light chain 3) isoforms, key markers to assess autophagy,
was measured in different tissues from non-stroked mice
to compare active autophagy (i.e. autophagic flux) across
tissues [20,21]. Specifically, we compared levels of the
most commonly used markers for autophagy, LC3I and
II, in brain, heart, lungs, liver, kidney, spleen, and skel-
etal muscle from 22–24 week old male C57BL6 mice
(Figure 1A-C). Additionally, we found a trend for LC3II
to accumulate following brief chloroquine treatment
(Figure 1D-E). Mice were treated with saline, or with
60 mg/kg chloroquine IP 4–6 hours prior to sacrifice to
block the final steps of autophagy allowing accumulation
of proteins that are normally degraded in active autoph-
agy thereby permitting quantification of autophagic flux.
Short-term treatment with chloroquine inhibits lyso-
somal enzyme activity in autolysosomes preventing the
turnover of contents accrued within autophagosomes.
The brain has both the high potential for constitutive au-
tophagy, i.e. it is primed with high levels of LC3I, and has
an actual high level of constitutive autophagic flux, or ac-
tive autophagy with high LC3II levels that appear to in-
crease with brief inhibition of autophagosome turnover.
Modulation of autophagy in MCAL stroke model
Initial studies using the MCAL stroke model were per-
formed to assess the optimal doses of chloroquine (30, 60and 90 mg/kg) and rapamycin (0.625, 1.25, 2.5 mg/kg) to
use in further experiments (Additional file 1: Figure S1).
The doses of 60 mg/kg for chloroquine and 1.25 mg/kg
for rapamycin were determined to be the most effica-
cious in limiting lesion size and to minimize non-
autophagic effects, and there was no difference in either
the saline or DMSO controls relative to non-stroked
mice. Infarct analyses by TTC staining after MCAL re-
vealed that only rapamycin treatment significantly re-
duced the stroke lesion size as compared to the saline
control group (50.8% relative reduction; 12.9% ±5.5%
versus 26.1% ±9.1%, P < 0.05) (Figure 2). Chloroquine
treatment also appears to reduce the infarct size, but
not significantly, compared to saline controls (29.1%
relative reduction; 18.5% ±10.1% versus 26.1% ±9.1%,
P = 0.36). The significant neuroprotection conferred by
rapamycin vanished when combined with the autophagy
inhibitor chloroquine (26.6% ±7.6% versus 26.1% ±9.1%,
P = 0.9). This is consistent with the two agents driving
autophagy in opposite directions and that together they
dysregulate autophagy. It also supports the idea that
rapamycin’s major effect is through induction of autoph-
agy rather than through other mechanisms, e.g. immuno-
suppression, since there were no synergistic, or additive
interactions with the combined treatments.
Modulation of autophagy in eMCAO stroke model
Next, we investigated the effect of pharmacologic modula-
tion of autophagy in the eMCAO stroke model (Figure 3).
Infarct analyses by TTC-staining after eMCAO revealed
that rapamycin is more effective in attenuating the stroke
injury lesion size (Figure 3A and 3B), in agreement with
the MCAL model data (Figure 2). Rapamycin treatment
significantly reduced the injury size compared to saline
control (43.8% relative reduction; 28.1% ±11.3% versus
50.1% ±7.1%, P < 0.005). Chloroquine also significantly
reduced the stroke injury (30.0% relative reduction;
35.0% ±13.8% versus 50.1% ±7.1%, P < 0.05), but to a lesser
extent than rapamycin. In agreement with the results from
MCAL experiments, the neuroprotection was lost in the
combination treatment group of rapamycin and chloro-
quine (P = 0.0009 for the interaction; 46.8% ±15.6% versus
50.1% ±7.1% for saline P = 0.6).
As shown in Figure 3C, rapamycin treatment im-
proved the neurological deficit score compared to the
saline treated control group (1.4 ± 0.5 versus 3.7 ± 0.6;
P < 0.01). Chloroquine treatment also showed an im-
proved neurological deficit score as compared to the saline
treated control group (2.0 ± 0.8 versus 3.7 ± 0.6; P < 0.05),
but less than that seen with rapamycin. When the two
treatments were combined the improvements in neuro-
logical deficit score seen with the individual treatments,
was lost (P = 0.0001 for the interaction; 3.7 ± 0.6 versus
































































































































Figure 1 Brain has the highest level of autophagy relative to other tissues. A). Brain, lung, heart, skeletal muscle, spleen, kidney and liver
were collected from non-stroked 22–24 week old male C57BL/6 J mice. The tissues were assessed for the autophagy markers, LC3 I and II, and
the loading control β-actin for non-muscle tissues and brain and GAPDH for muscle tissues and brain. The top subpanel in (A) is a 5-fold longer
exposure than the subpanel immediately below it to highlight LC3I/II in tissues that were below the level of detection in the lower subpanel. The
lower subpanel (exposed for 1 minute) shows the expression of brain LC3I/II relative to other tissues better, and with a better dynamic range, without
the loss of linearity seen with the longer exposure. All subpanels in (A) are from the same blot, one tissue not used in other blots assessed in
panels B & C was cropped out. A white space was left to show where the cropping occurred. B). Quantitation of non-muscle tissues normalized
to β-actin and compared to brain. All quantitations were performed on film exposed for one minute, with equal antibody concentrations and incubation
used on each tissue set. C). Quantitation of muscle tissues and brain normalized to GAPDH and compared to brain. D). Two saline treated and
two chloroquine treated brain samples are shown as representative examples. The chloroquine treated mice show apparent accumulation of
LC3II following chloroquine treatment (five hours with 60 mg/kg chloroquine) to assess autophagic flux. E). LC3II levels in brain samples from
four chloroquine treated and five saline treated mice were measured. The accumulation of LC3II is noticeable, but not significantly different
when quantitated against GAPDH. (* = p < 0.05, ** = p < 0.01, *** = p < 0.005, **** = p < 0.0001).
Buckley et al. Experimental & Translational Stroke Medicine 2014, 6:8 Page 5 of 9
http://www.etsmjournal.com/content/6/1/8The rapamycin only treatment seems most effective in
improving survival post-stroke (Figure 3D). While not
significant (P = 0.34), rapamycin treatment appears to in-
creased survival at 48 hours post-stroke (10 out of 11
animals; ~91% survival) in comparison to the saline
treated group (7 out of 11 animals survived; ~64%
survival), chloroquine treatment (7 out of 11 animals
survived; ~64% survival) or with the combined treat-
ment group of rapamycin and chloroquine (3 out of 5
animals; ~60%).
Discussion
Mizhuma et al., in a ground-breaking 2004 study [21],
demonstrated high levels of LC3 isoforms, key markers ofautophagy, in the brains of transgenic mice overexpressing
a GFP-LC3 construct. The suggestion of high levels of
LC3, and therefore autophagy, in the brain remained
controversial for many years as research in neurodegen-
erative diseases revealed high levels of double mem-
brane autophagosomes. This was incorrectly interpreted
to conclude that the brain had a low level of autophagy,
which is only up-regulated during neurodegeneration or
injury [22-24]. In an effort to confirm if the brain has
endogenously high levels of autophagy, we collected
brain, heart, lungs, liver, kidney, spleen, and skeletal
muscle, metabolically active tissues that have been thought
to undergo active autophagy constitutively [25-27]. These
were collected from 22–24 week old male C57BL6
Figure 2 Enhancement of autophagy with rapamycin decreases infarct size in MCAL mouse models of ischemic stroke injury. A). 8–12
week old male C57BL/6 J mice underwent MCAL stroke injury, and were treated twice (0 and 24 hours) with either saline, rapamycin (rapa) to
enhance autophagy, chloroquine (CQ) to inhibit autophagy, or a combination of rapa and CQ. Infarct size analysis using 2% TTC staining
(n = 9 mice per group). B). Quantitation of panel A data (* = p < 0.05). Note tissue drop out in the lesion site is due to the fragility of the
tissue, not surgical damage.
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demonstrate that, relative to these tissues, brain expresses
LC3I, the precursor to LC3II, and the active autophagic
form, LC3II, at significantly higher levels. In vitro autopha-
gic flux is a more reliable indicator of autophagic activity
than static snap-shots of autophagic pathway markers,
as is most commonly reported in the stroke literature
[20,28]. We attempted to assess autophagic flux using a
short-term in-vivo chloroquine treatment compared to
untreated animals since there has not been a previous
report of in vivo autophagic flux for murine brain.
Chloroquine raises intracellular pH including lysosomal
compartments thereby inhibiting acid-dependent lyso-
somal proteolytic degradation of cellular components
within the autolysosome. This allows accumulation of
autophagosomes and their contents including autophagy
marker proteins. Moreover, when exposed to short-term
autophagic inhibition these levels remain high. While the
chloroquine treated brains do not have a statistically sig-
nificant increase in LC3II, there is a strong trend support-
ing high autophagic flux, and importantly this is not
abrogated by flux inhibition. If flux were low, or dysfunc-
tional, there would be no change, or a decrease in LC3II,
and potentially in LC3I, too. Future studies will examine
optimizing in vivo inhibition of autophagosome turnover,
both in terms of the inhibitor and its application, to assess
in vivo autophagic flux. Importantly, the higher levels of
both LC3I and LC3II suggest that brain has both the cap-
acity for the initiation of higher levels of autophagy acutely
in response to stress, as well as actually having a higherbackground constitutive autophagic flux. This sug-
gests an enhanced ability to support constitutively
active autophagy is critical for adult brain, possibly
due to the high metabolic demand of the brain and
lack of storage of nutrients like glucagon, which ren-
ders the brain, and neurons in particular, vulnerable
to ischemic insult [29]. A high level of preformed au-
tophagy constituents, (e.g. LC3I and II) ready to rap-
idly support autophagy, might provide an inherent
degree of energy and nutrient buffering to the brain.
Therefore, we hypothesized that driving autophagy is
protective following stroke.
Autophagy has been well established to play a role in
ischemic injury and neurodegeneration although the
role(s) is complicated and not fully delineated [6,26,30].
For example, sustained stress may lead to depletion of
key preformed autophagy pathway or regulatory proteins
needed for successful protective autophagy [31-33]. Con-
sequently, this may result in compromised or dysfunc-
tional autophagy. While the role of autophagy in adult
cerebral ischemia is still not clear, its induction appears
to be protective and of potential translational value in
limited slow reperfusion. However, whether autophagy is
protective to neurons and other brain cells in response to
ischemia may also be contextual, relative to the extent of
ischemia and the presence, or type, of reperfusion. In
earlier autophagy and stroke studies, tsMCAO with rapid
complete reperfusion, was the most commonly used
model. Importantly, the hyperemic effect of rapid and
immediate complete reperfusion seen with this type of
BDC
A
Figure 3 Rapamycin improves infarct size, survival, and neurological outcomes after eMCAO. The eMCAO study was performed with two
independent sets of mice. In the first set there were 6 mice starting in the rapamycin, chloroquine and saline control groups they are included in
the data in panels B & D, however, they were not assessed for behavior. The second set of mice had an n = 5 for each group, it also included a
rapamycin and chloroquine dual treated group not included in the first set of mice. All of these mice received behavioral assessments and are
included in the data for panels B, C & D. A). Representative TCC stained brain sections 48 hours post-eMCAO stroke (n = 10 for rapamycin
treatment, n = 7 for vehicle control and chloroquine treatments, and n = 3 for rapamycin and chloroquine dual treatment. These numbers
represent the surviving animals at 48 hours out of eleven starting mice for the saline, chloroquine and rapamycin treated groups and five
animals for the rapamycin and chloroquine dual treatment group and are the set of mice measured in panels B & D. B). Normalized lesion
volume at 48 hours post-eMCAO stroke. C). Quantitation of the Bederson neurological deficit scores by treatment group (n = 5 out of 5 surviving
mice for rapamycin treatment, n = 4 out of 5 surviving mice for chloroquine treatment, n = 3 out of 5 surviving animals for vehicle control
and rapamycin and chloroquine dual treatment groups). D). 48 hour post-eMCAO survival ratio (number of surviving mice vs total number of
eMCAO stroked and treated mice) (n = 11 for vehicle control, chloroquine, and rapamycin treatments, and n = 5 for rapamycin and chloroquine dual
treatment). Note tissue drop out in the lesion site is due to the fragility of the tissue, not surgical damage. (* = p < 0.05, ** = p < 0.01, *** = p < 0.005).
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human stroke. It can result in CBF rebounding above the
pre-ischemic basal level. This effect may provide protection
to both the ischemic core and penumbra when combined
with pre-clinical treatments that reduce secondary injury,however, such treatments may not be protective with slow
reperfusion [10]. Therefore, it may be important to find
treatments that are protective when reperfusion is limited.
Ultimately this study supports the use of rapamycin,
or analogues, as well as potentially other “pro-autophagic”
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tial recanalization and delayed reperfusion. Autophagy
has recently been reported to potentially have two dis-
tinct roles during “ischemia” and “reperfusion” in stud-
ies of myocardial infarction [9]. Induction of autophagy
provided protection during ischemia more than during
reperfusion [34]. However, the timing of autophagy in-
duction might be critical to obtain benefits during
stroke. Therefore, future studies are still warranted.
Importantly, given that the overwhelming majority of
stroke patients do not have reperfusion reversals within
the short time frame seen with tsMCAO, the increased
vulnerability to secondary molecular cell death effects is
not an issue. Indeed, this vulnerability may even be
blocked by induction of active autophagy. Therefore, au-
tophagy inducing interventions after stroke during the
“golden hour” [10,12] may limit the expansion of penum-
bra and the necrosis of ischemic core. Rapamycin is
a safe drug to use, possibly even in the presence of
hemorrhagic stroke [35,36]. Therefore, rapid induction of
autophagy, allowing neurons to survive loss of nutrients
and energy production by using nutrient recycling and
anaerobic ATP production may prevent, or significantly
reduce, the perfusion/metabolism mismatch responsible
for primary infarct expansion into the penumbra and be-
yond. This may allow a longer window of time for in-
creased spontaneous recanalization based reperfusion
and penumbral recovery, or even allow tPA use to be ex-
tended out in time and therefore to a larger percentage
of the stroke patient population.
Conclusion
By comparing both the enhancement and inhibition of
autophagy side-by-side in two different pathophysio-
logically relevant models of ischemic injury, we were
able to demonstrate that enhancement of autophagy
by low dose rapamycin has advantages over its inhib-
ition by chloroquine after stroke. Given rapamycin’s
well-characterized safety profile, its use has significant
translational potential, both due to its induction of au-
tophagy, and even its secondary effects on inhibition of
tissue destructive immune system responses. Based on
the potential difference in response to autophagy regula-
tion with rapid reperfusion in myocardial ischemic injury
[9] it is important to determine if the positive effects seen
in the eMCAO model on stroke injury outcomes are still
present following rapid reperfusion with tPA. Since the
eMCAO model used here is also suitable to utilize with
IV-tPA thrombolysis, further post-eMCAO studies on
the safety and benefits of either rapamycin, or chloro-
quine, as adjuvants to IV-tPA are warranted. Future stud-
ies will also address effects of age, gender and disease
comorbidities (e.g. hypertension and diabetes) on stroke
outcomes with modulation of autophagy.Additional file
Additional file 1: Figure S1. Determination of optimally protective
dose for rapamycin and chloroquine in an MCAL mouse model of
ischemic stroke injury. A). Representative anterior to posterior TCC
stained brain sections 48 hours post-MCAL stroke treated with 40%
DMSO (Vehicle Control), 1.25 mg/kg rapa, or 2.5 mg/kg rapa. Additionally
a 0.625 mg/kg rapamycin group was assessed and was not different from
the vehicle control (not shown) suggesting above 1.25 mg/K the protective
effect was not enhanced. B). The 0.625 mg/kg rapa was comparable to
DMSO control and was not repeated, both 1.25 mg/kg and 2/5 mg/kg
were found to significantly reduce infarct size (p < 0.001), the lower dose of
1.25 mg/kg rapa was chosen to limit off target effects. C). Representative
TCC stained brain sections 48 hours post-MCAL stroke treated with Saline
(Vehicle Control), 30, 60, or 120 mg/kg CQ, D). The 30 and 120 mg/kg doses
of CQ did not significantly improve infarct size, but the 60 mg/kg CQ
did (p < 0.05) and was chosen for all other experiments.
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